home / stock / btai / btai news

BTAI News and Press, BioXcel Therapeutics Inc. From 01/07/26

Stock Information
Company Name: BioXcel Therapeutics Inc.
Stock Symbol: BTAI
Market: NASDAQ
Website: bioxceltherapeutics.com
Menu
BTAI BTAI Quote BTAI Short BTAI News BTAI Articles BTAI Message Board
Get BTAI Alerts

News, Short Squeeze, Breakout and More Instantly...
BTAI - BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug App...
BTAI - BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript

2025-12-11 06:42:48 ET BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home December 8, 2025 10:02 AM EST... Read the full article on Seeking Alpha For further details see: BioXcel Therapeutics, Inc. (BTAI) D...

BTAI - Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- As mil...

BTAI - BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84

2025-11-12 07:40:05 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call ...
BTAI - BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported financial results for the third quarter of 2025 and provided an update o...

BTAI - Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties t...

BTAI - BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive results from the correlation study related to exploratory effi...
BTAI - BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) , a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXce...

BTAI - BioXcel regains compliance with Nasdaq listing rule

2025-09-18 07:41:38 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call ...

BTAI - BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualificatio...
Previous 10 Next 10